MRI-Targeted biopsy matches standard method in prostate cancer detection

NCT ID NCT02050542

Completed Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using an MRI to guide prostate biopsies could detect cancer as well as the standard 12-sample systematic biopsy. Researchers enrolled 108 men aged 45-75 with elevated PSA levels and suspicious MRI findings. They compared the cancer detection rates of 3 targeted biopsies guided by MRI-ultrasound fusion against the standard 12-sample approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

CHU Cochin

Paris, 75014, France
CHU Grenoble

Grenoble, 38043, France
CHU Pitié salpêtrière

Paris, 75013, France
CHU Toulouse Rangueil

Toulouse, 31076, France
Chu Edouard Herriot

Lyon, 69437, France
Clinique Pasteur

Toulouse, 31076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.